A Clearer View from JPM 2026 – Day Four
The final day of JPM 2026 didn’t bring any late-breaking megadeals or big surprise announcements but there was plenty to keep biotech watchers engaged to the end. Our Biomedtracker team has summarized all the presentations in their Day Four report which you can download here, and below are a few highlights to ponder. Large cap […]
A Clearer View from JPM 2026 – Day Three
Day Three of JPM 2026 continued with a sense of both positivity and stability – both noticeably lacking in recent years. Here are a few of the highlights from the Biomedtracker team and you can catch up with all the action from Day Three in our full report which is available here. Mega cap momentum […]
A Clearer View from JPM 2026 – Day Two
Day Two at JPM carried a similar message from Day One: focus where you can win, deploy capital with discipline, and back assets with real clinical traction. Our Biomedtracker team has captured every detail in the full report which is available here, but here are some highlights. Mega caps sharpen their growth engines AstraZeneca’s session […]
A Clearer View from JPM 2026 – Day One
Here we are again. January means the JP Morgan Healthcare Conference and all eyes in the pharma and biotech space turn to San Francisco. Our Biomedtracker team is providing daily reports to bring you the highlights of each day’s activities. There’s loads to digest in the full Day One report, so here are a few […]
How Biotechs Can Win Capital in 2026: Highlights from Evaluate’s Financing Forum
January may be upon us but allow me one chance to look back at one of December’s highlights; Evaluate’s event that took place in London. Evaluate Financing Forum: Biotech Strategies for Accessing Capital saw more than 50 professionals from pharma, biotech and financing come together for a morning of networking and knowledge sharing about biotech […]
Strategic Deals and Investment Moves Influencing the GLP-1 Marketplace
While the rapid growth of the GLP-1 and obesity market presents enormous financial opportunities for life sciences companies, it also carries legal, regulatory, and reimbursement risks. With that in mind, Norstella were recently invited to present a session at the American Conference Institute Inaugural Summit on GLP-1 Law & Policy, Using deals data from Evaluate […]
Back from BIO: The Evolving Biotech Investment Landscape
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the state of play for biotechs in recent years. Fortunately, while this may be only a partial exaggeration, there were many more positive notes as well. Fresh from my third BIO International and after digesting […]
Three Things we Learned in our World Preview 2025 Webinar
Every year, I am hugely fortunate to work with our team of experts to create the Evaluate World Preview report. Now in its 18th year, the World Preview offers a data-rich look at the future of the pharmaceutical industry. It’s full of forecast data that help to paint a picture of the shifting sands of […]
How can Pharma Navigate Turbulent Seas? Find out in our World Preview Webinar
The Evaluate World Preview report is a staple of the pharma calendar. The 2025 edition has just been published, marking the 18th year of providing forecast and trend insights to decision makers across the industry. If you’re not familiar with the World Preview, I recommend taking a look. Not only does it provide a wealth […]
Three Things we Learned in our 2025 Preview Webinar
The first Evaluate webinar of the year is in the bag. Based on our 2025 Preview report, this session brought together three of our industry experts to discuss what the year ahead might hold for pharma. They may not have had a crystal ball, but they had plenty of detailed data and insight which is […]
